SUBSCRIBE
SUBSCRIBE
News   Policy

IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets

October 30, 2009 | 
1 min read
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.
Legal
Abbott Laboratories
MORE ON THIS TOPIC
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
February 27, 2026
 · 
7 min read
 · 
Heather McKenzie
President Donald Trump calls out the first patient to access his TrumpRx drug platform during his State of the Union address at the U.S. Capitol on Tuesday, February 24, 2026.
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
 · 
2 min read
 · 
Annalee Armstrong
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
 · 
3 min read
 · 
Tristan Manalac
Illustration of man walking in the beach between two blue seas, surreal abstract path concept
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
 · 
3 min read
 · 
Nick Paul Taylor